US4358439A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Cyclooctapeptides
Assignee: Novartis Corp
•
Filing: 1980-12-15
•
Granted: 1982-11-09
•
Expires: 2000-12-15
Abstract
Abstract Cyclic peptides of the formula <IMAGE> (I) in which trp represents L-Trp, D-Trp, or an analogous radical which carries a halogen atom in the indole nucleus, AcA represents hydrogen, or an acyl radical Ac of a carboxylic acid present at the epsilon -amino group, A represents L-Phe, D-Phe, L-Phg or D-Phg, or a corresponding radical having a substituted or saturated phenyl ring, and B represents the residue of a gamma - or delta -amino-lower alkanecarboxylic acid which may carry an optionally substituted cyclic hydrocarbyl radical Ar, and also pharmacologically tolerable salts and therapeutically acceptable complexes thereof can be used as an antidiabetic in an analogous manner to somatostatin. They can be obtained by conventional processes of peptide chemistry, especially by cyclisation of corresponding linear peptides.
Inventors
- 👤 Peter Sieber
- 👤 Bruno Kamber
- 👤 Hans Rink
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 16:55
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/655; C07K14/6555; A; A61; A61P; A61P5/00; A61P5/02; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/16
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
102 words
A cyclic octapeptide of the formula ##STR16## in which trp represent L-Trp, D-Trp or an analogous radical which carries a halogen atom in the indole nucleus, Ac A represents hydrogen, A represents L-Phe, D-Phe, L-Phg or D-Phg, or the analogus residues having the cyclohexyl or p-hydroxyphenyl radical substituted for the phenyl radical, and B represents Gaba which is the residue of the unsubstituted α-aminobutyric acid, or Gaba (Ar), which is an analogus residue carrying in the β-position a mono- or bicyclic aryl radical Ar having not more than 12 carbon atoms, and also pharmacologically tolerable salts and activity-prolonging therapeutically acceptable complexes thereof.
Claim 2
Dependent Claim
102 words
A cyclic octapeptide of the formula ##STR16## in which trp represent L-Trp, D-Trp or an analogous radical which carries a halogen atom in the indole nucleus, Ac A represents hydrogen, A represents L-Phe, D-Phe, L-Phg or D-Phg, or the analogus residues having the cyclohexyl or p-hydroxyphenyl radical substituted for the phenyl radical, and B represents Gaba which is the residue of the unsubstituted α-aminobutyric acid, or Gaba (Ar), which is an analogus residue carrying in the β-position a mono- or bicyclic aryl radical Ar having not more than 12 carbon atoms, and also pharmacologically tolerable salts and activity-prolonging therapeutically acceptable complexes thereof.
Claim 3
Dependent Claim
92 words
A cyclic octapeptide according to claim 1, in which, formula I trp represents D-Trp or D-(5F)Trp, AC A represents hydrogen, A represents L-Phe, D-Phe, L-Phg or D-Phg, or the analogus residues having the cyclohexyl or p-hydroxyphenyl radical substituted for the phenyl radical, and B represents Gaba which is the residue of the unsubstituted α-aminobutyric acid, or Gaba (Ar), which is an analogus residue carrying in the β-position a mono- or bicyclic aryl radical Ar having not more than 12 carbon atoms, and also pharmacologically tolerable salts and activity-prolonging therapeutically acceptable complexes thereof.
Claim 4
Dependent Claim
66 words
A cyclic peptide, according to claim 1, in which, in the formula I, trp represents D-Trp or D-(5F)Trp, Ac A represents hydrogen, A represents L-Phe, D-Phe, L-Phg or D-Phg, or the analogus residues having the cyclohexyl or p-hydroxyphenyl radical substituted for the phenyl radical, and B represents the residue of the unsubstituted γ-aminobutyric acid, and also pharmacologically tolerable salts and activity prolonging therapeutically acceptable complexes thereof.
Claim 5
Dependent Claim
15 words
[D-Trp 8 ,Phe 12 ,Gaba 13 ]-cyclosomatostatin(6-13)-octapeptide and pharmacologically activity prolonging therapeutically acceptable complexes thereof.
Claim 6
Dependent Claim
15 words
[D-Trp 8 ,Phe 12 ,Gaba 13 ]-cyclosomatostatin(6-13)-octapeptide and pharmacologically activity prolonging therapeutically acceptable complexes thereof.
Claim 7
Dependent Claim
15 words
[D-Trp 8 ,D-Phe 12 ,Gaba 13 ]-cyclosomatostatin(6-13)octapeptide and pharmacologically activity prolonging therapeutically acceptable complexes thereof.
Claim 8
Dependent Claim
15 words
[D-Trp 8 ,D-Phe 12 ,Gaba 13 ]-cyclosomatostatin(6-13)octapeptide and pharmacologically activity prolonging therapeutically acceptable complexes thereof.
Claim 9
Dependent Claim
29 words
A pharmaceutical preparation for the treatment of diabetes and/or gastrointestinal bleeding in humans and mammals, containing an effective amount of a compound according to any one of claims 1-5.
Claim 10
Dependent Claim
41 words
A therapeutic method for the treatment of diabetes and/or gastrointestinal bleeding in humans and mammals by administration of a therapeutically effective dose of a compound according to any one of claims 1-5 alone or in the form of a pharmaceutical preparation.
References Cited (Backward Citations)
US3875207A
Cited
US3944590A
Cited
US3725380A
Cited
US3872074A
Cited
US3862113A
Cited
US4146612A
Cited
US4238481A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-11-08 | 1986-05-10 | 1986-11-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-11-08 | 1990-05-10 | 1990-11-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-11-08 | 1994-05-10 | 1994-11-09 | $7700.00 | Window Closed / Lapsed |